Objective: To provide trainees from all backgrounds (basic/translational research, medicine, industry) with an up-to-date overview of the fundamentals of ovarian cancer, topics under debate and emerging areas in research and clinical care.
Welcome, Opening Remarks
Lynne-Marie Postovit, Co-Chair CCOCR 2018 Organizing Committee
Elisabeth Baugh, Ovarian Cancer Canada
Pathobiology of ovarian cancer
Basic overview of ovarian cancer pathobiology
Trainees will learn about the unique histopathology of the most common types of ovarian cancer, including characteristic biomarkers.
Speaker: Martin Koebel, MD; University of Calgary
What is the source of high-grade serous carcinoma?
Trainees will be presented with up-to-date data on a fallopian tube vs. ovarian origin of high-grade serous carcinoma, and potential implications on early detection and clinical management.
Speaker: Ted Brown, PhD; University of Toronto
Endometriosis: A precursor of ovarian cancer?
Trainees will be presented with data supporting the role of endometriosis in endometrioid and clear cell carcinoma.
Speaker: Michael Anglesio, PhD; BC Cancer Agency
Break-out session 1: Origins of ovarian cancer
Overview of current clinical management
Description of the “typical” clinical course of women from time of diagnosis, through treatment, to end of life.
Speaker: Helen Steed, MD.; University of Alberta
Emerging role of immune therapy in ovarian cancer treatment
Trainees will be presented with data on different immune therapies that may benefit women with ovarian cancer.
Speaker: Brad Nelson, PhD.; University of Victoria.
Is neoadjuvant chemotherapy beneficial or harmful?
Trainees will be presented with conflicting data on the impact of neoadjuvant chemotherapy in women with ovarian cancer.
Speaker: Taymaa May, MD. Princess Margaret Cancer Centre.
Break-out session 2: Ovarian cancer treatment.
Lunch - Living with Cancer: A Perspective
Moderator: John Robinson, PhD. University of Calgary
Risk and prevention
Inherited predisposition and genetic counselling
Trainees will learn about the contribution of inherited mutations in BRCA1 and 2, Lynch Syndrome genes and emerging moderate risk genes to hereditary ovarian cancer, and the important role of genetic counselling.
Speaker: Maria Farag, MSc, CCGC University of Alberta Hospital
Surgical and non-surgical options for ovarian cancer risk reduction
Trainees will learn about the surgical options for risk reduction in women at high risk and the general population, in addition to non-surgical alternatives such as oral contraceptives and aspirin.
Speaker: Alicia Tone, PhD. Princess Margaret Cancer Centre.
Break-out session 3: genetic predisposition
The scientific tool box
Experimental models of ovarian cancer
Trainees will learn about the advantages and drawbacks of available model systems, such as cell culture, patient-derived xenografts and mouse models.
Speaker: Barbara Vanderhyden, PhD; University of Ottawa
“Omics” of ovarian cancer
Trainees will learn about next-generation sequencing techologies and new biologic samples of interest, such as circulating tumour DNA.
Speaker: Jim Petrik, PhD. University of Guelph
Closing and Evaluations